Bridging COI/COC Across Countries/Regulators


Published on 30/11/2025

Bridging COI/COC Across Countries/Regulators

In the evolving landscape of biotechnology and pharmaceuticals, ensuring the integrity and safety of biologics through rigorous validation processes is paramount. This guide focuses on bridging the gaps in Chain of Identity (COI) and Chain of Custody (COC) across different regulatory environments, specifically guided by frameworks and expectations from authorities such as the US FDA, EMA, MHRA, and PIC/S.

Understanding Chain of Identity and Chain of Custody

The Chains of Identity and Custody are crucial in the lifecycle of biologics and Advanced Therapy Medicinal Products (ATMPs). These concepts ensure that products are tracked and maintained under stringent controls from initial collection through the manufacturing and testing phases. Establishing robust COI and COC systems not only reinforces compliance with Good Manufacturing Practices (GMP) but also enhances traceability, which is vital for regulatory inspections.

Chain of Identity (COI) refers to the continuous tracking of biological samples throughout the manufacturing process. It ensures that every sample is accurately identified and that no mix-ups occur. COI is fundamental in viral clearance validation, where the integrity of the product’s source can directly impact its safety and efficacy.

Chain of Custody (COC) on the other hand, involves the process of collecting, transporting, and storing the samples in a way that maintains a documented chain of ownership and control. This process is critical to ensure that the samples have not been tampered with during the transit or storage phases.

Regulatory Framework Regarding COI/COC

Establishing COI and COC processes must comply with the regulatory expectations laid out by different health authorities. In the United States, the FDA mandates strict adherence to guidelines which include aspects from both ICH Q5A(R2) and the expectations for potency identity CQAs (Critical Quality Attributes). Meanwhile, the EMA and MHRA provide complementary guidelines that emphasize regulatory compliance across Europe.

  • FDA Process Validation: Emphasizes the need for rigorous validation protocols that include built-in checkpoints for COI and COC.
  • ICH Q5A(R2): Outlines strategies for the assessment of viral clearance which inherently involves COI and COC systems.
  • Annex 1 Aseptic Controls: Highlights best practices for maintaining integrity and control over products in sterile processing environments.

Implementing Effective COI/COC Systems

Successful implementation requires a multi-faceted approach that merges technological advancements with quality management practices while fulfilling all regulatory obligations. Here are the steps for developing effective COI and COC systems:

Step 1: Define Your Processes

Begin with a detailed mapping of the entire lifecycle of your product, from source material to the final dosage form. Clearly outline each step where COI and COC can be monitored and recorded. This includes:

  • Source collection (e.g. human, animal materials)
  • Processing and testing stages
  • Packaging and distribution methodologies

Step 2: Integrate Technology

Modern systems increasingly rely on technology to ensure compliance. Closed systems and single-use systems present significant advantages in maintaining COI and COC:

  • Closed Systems: Minimize the risk of contamination and provide automated tracking of product transfers.
  • Single-Use Systems: Offer a streamlined approach to handling samples, ensuring that the material used has not been compromised.

Implementing these systems aligns well with aseptic controls as outlined in Annex 1 and directly supports your viral clearance validation efforts.

Step 3: Documentation and Training

Proper documentation practices are foundational to maintaining COI and COC. Every process should be accompanied by detailed records that can be audited to confirm adherence to protocols. Regular employee training and ongoing competency assessments are essential to ensure that personnel are well-versed in not only the compliance requirements but also the operational protocols necessary for successful implementation.

  • Develop Standard Operating Procedures (SOPs) that detail the COI and COC protocols.
  • Ensure robust record-keeping practices that include batch records, sample testing results, and transport manifests.
  • Conduct training for all staff involved in handling the samples to ensure compliance with existing Regulations.

Viral Clearance Validation: Focus on Spiking Studies

Viral clearance validation is a critical aspect of biologics manufacturing whereby the safety of the product is evaluated concerning viral contaminants. Spiking studies serve as a key methodology within this validation framework.

Understanding Spiking Studies

Spiking studies involve introducing a known quantity of a viral pathogen into a biological product to assess the manufacturing process’s ability to eliminate or inactivate the contaminant. This practice provides a robust measure of the viral clearance capacity within the manufacturing process.

Step 1: Select Appropriate Viruses

The first consideration in executing spiking studies is the selection of relevant viral pathogens. Factors to consider include:

  • Relevance to the therapeutic context of the final product.
  • Regulatory expectations regarding viral clearance (e.g. ICH Q5A(R2)).
  • The likelihood of the pathogens’ presence during the manufacturing process.

Step 2: Develop Study Design and Methodology

Designing the study involves defining clear objectives, determining the necessary controls, and establishing the acceptability criteria for clearance efficacy. Important elements include:

  • The concentration of the viral spiking agent.
  • The types of assays used for measurement (e.g. PCR, cell culture assays).
  • Documenting the entire process and results for regulatory submissions.

Step 3: Conduct the Study

Perform the study under stringent conditions, using both closed and single-use systems where possible to mitigate contamination risk.

Monitoring and Quality Management

Monitoring and continuous quality management are essential to maintain effective COI and COC systems over time. This involves:

Establishing a Quality Control Framework

Integrate a rigorous Quality Control (QC) framework that specifies regular audits, where COI and COC documents are reviewed for completeness and accuracy. This should occur during different phases of production and immediately following major checkpoints.

Conducting Regular Internal Audits

Regular internal audits are vital to ensure adherence to established protocols and regulatory requirements. For example, a comprehensive review of record-keeping practices can highlight areas of improvement in the documentation process. Be sure to:

  • Review adherence to SOPs associated with both COI and COC.
  • Ensure that training records are complete and up to date.
  • Regularly test and validate the effectiveness of installed technological solutions.

Tailoring PPQ/CPV for ATMP Compliance

Performance Qualification (PQ) and Continued Process Verification (CPV) must be tailored specifically for ATMPs due to their complex nature. The aim is to ensure ongoing compliance with both COI and COC requirements, while also meeting all established CQAs.

Step 1: Defining Your PPQ Strategy

Start by defining your Process Performance Qualification strategy. This includes identifying critical parameters and establishing acceptance criteria pertinent to both COI/COC practices and product consistency.

Step 2: Implement Continuous Monitoring

CPV involves the continuous collection of data on the manufacturing process to ensure sustained process performance. Make sure to:

  • Utilize real-time data analytics to identify trends and issues regarding COI and COC adherence.
  • Adjust processes as needed based on the data collected, continually refining COI and COC systems to enhance reliability.

Conclusion: Bridging Regulatory Gaps and Ensuring Compliance

Bridging the gap in COI and COC across various regulatory frameworks is indeed a multifaceted challenge faced by pharmaceutical professionals. By meticulously outlining processes, leveraging technology, and adhering to guidelines from health authorities such as the EMA, companies can ensure the integrity of their biologics and ATMPs throughout their lifecycle.

In summary, continual refinement of processes related to viral clearance validation, especially concerning spiking studies and aseptic controls like closed and single-use systems, is essential. Fulfilling these obligations not only supports regulatory compliance but also underpins the broader goal of patient safety and product efficacy.